Lantheus Holdings (LNTH) Debt/Equity Ratio: History & Chart

Lantheus Holdings, Inc.(LNTH)

Drug Manufacturers - Specialty & Generic · Bedford, MA

$99.96-0.23 (-0.23%)

Delayed quote: Oct 6, 2026, 1:45 PM EDT

About Lantheus Holdings, Inc.

Lantheus Holdings, Inc. is a global pharmaceutical company dedicated to the development, manufacturing, and commercialization of advanced diagnostic and therapeutic agents. Their mission is to empower clinicians worldwide in the accurate diagnosis and effective treatment of a wide spectrum of conditions, particularly heart disease, various cancers, and other serious illnesses. Their current diagnostic portfolio features several key products: DEFINITY, a microbubble ultrasound contrast agent for cardiac evaluations; TechneLite, a technetium generator essential for nuclear medicine; Xenon-133, used to assess pulmonary function; Neurolite, which helps identify stroke-damaged areas in the brain; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 for detecting cardiovascular disease; and Gallium-67, utilized in identifying infections and cancerous tumors. They also offer the Automated Bone Scan Index, a tool for quantifying prostate cancer burden from bone scans; PYLARIFY, designed for visualizing lymph nodes, bone, and soft tissue metastases to detect recurrent or metastatic prostate cancer; and Cobalt (Co 57), a non-pharmaceutical radiochemical. In the therapeutic space, Lantheus provides AZEDRA, a radiopharmaceutical treatment for both adult and pediatric patients, and RELISTOR, a medication addressing opioid-induced constipation. The company's robust development pipeline includes promising innovations such as flurpiridaz F 18, an agent for assessing myocardial blood flow; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in both children and adults; PYLARIFY AI, an AI-powered medical device software for standardized quantitative analysis of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. Lantheus serves a diverse client base, including radiopharmacies, distributors, integrated delivery networks, hospitals, clinics, and group medical practices. They foster strategic collaborations with notable industry partners such as NanoMab Technology Limited, Bausch Health Companies, Inc., GE Healthcare Limited, Curium, Bayer AG, CytoDyn Inc., ROTOP, FUJIFILM, Regeneron Pharmaceuticals, Inc., and POINT Biopharma US Inc. Established in 1956, Lantheus Holdings, Inc. maintains its corporate headquarters in North Billerica, Massachusetts.

Bedford, MA

1,193 employees

www.lantheus.com

Healthcare / Drug Manufacturers - Specialty & Generic

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
CEO: Mary Anne Heino

View full financials

LNTH Debt to Equity Ratio Metrics

DEBT TO EQUITY RATIO

0.48

DEBT TO EQUITY RATIO AVG TTM

0.54

DEBT TO EQUITY RATIO AVG 3Y

0.57

DEBT TO EQUITY RATIO AVG 5Y

0.52

DEBT TO EQUITY RATIO AVG 10Y

0.76

DEBT TO EQUITY RATIO AVG 15Y

N/A

DEBT TO EQUITY RATIO AVG 20Y

N/A

CURRENT VS TTM AVG

-11.49%

CURRENT VS 3Y AVG

-17.14%

CURRENT VS 5Y AVG

-7.52%

CURRENT VS 10Y AVG

-37.34%

CURRENT VS 15Y AVG

N/A

CURRENT VS 20Y AVG

N/A

SECTOR MEDIAN · HEALTHCARE

0.11

median of 746 covered companies

CURRENT VS SECTOR MEDIAN

+333.11%

vs the sector median at left

NAME	MARKET CAP	DEBT TO EQUITY RATIO	TTM	3Y	5Y
Lantheus Holdings, Inc. (LNTH)	$6.51B	0.48	0.54	0.57	0.52
Amneal Pharmaceuticals, Inc. (AMRX)vs ›	$6.50B	84.54	74.29	41.61	30.23
Hims & Hers Health, Inc. (HIMS)vs ›	$6.51B	4.77	1.04	0.53	0.36
Immunovant, Inc. (IMVT)vs ›	$6.48B	0.00	0.00	0.00	0.00
Chemed Corporation (CHE)vs ›	$6.65B	0.40	0.15	0.19	0.23
Rhythm Pharmaceuticals, Inc. (RYTM)vs ›	$6.19B	0.02	0.01	0.01	0.01
Alkermes plc (ALKS)vs ›	$6.99B	0.87	0.04	0.19	0.25
GRAIL Inc. (GRAL)vs ›	$5.94B	0.04	0.04	0.03	0.04
Ligand Pharmaceuticals Incorporated (LGND)vs ›	$5.90B	1.17	0.23	0.15	0.27
Iovance Biotherapeutics, Inc. (IOVA)vs ›	$5.91B	0.06	0.08	0.11	0.11

NAME

MARKET CAP

DEBT TO EQUITY RATIO

TTM

Lantheus Holdings, Inc. (LNTH)

$6.51B

0.48

0.54

0.57

0.52

Amneal Pharmaceuticals, Inc. (AMRX)vs ›

$6.50B

84.54

74.29

41.61

30.23

Hims & Hers Health, Inc. (HIMS)vs ›

$6.51B

4.77

1.04

0.53

0.36

Immunovant, Inc. (IMVT)vs ›

$6.48B

0.00

Chemed Corporation (CHE)vs ›

$6.65B

0.40

0.15

0.19

0.23

Rhythm Pharmaceuticals, Inc. (RYTM)vs ›

$6.19B

0.02

0.01

Alkermes plc (ALKS)vs ›

$6.99B

0.87

0.04

0.19

0.25

GRAIL Inc. (GRAL)vs ›

$5.94B

0.04

0.03

0.04

Ligand Pharmaceuticals Incorporated (LGND)vs ›

$5.90B

1.17

0.23

0.15

0.27

Iovance Biotherapeutics, Inc. (IOVA)vs ›

$5.91B

0.06

0.08

0.11

Debt to Equity Ratio FAQ

What is the debt to equity ratio for Lantheus Holdings, Inc. (LNTH)?

The debt to equity ratio for LNTH stock is 0.48.

Is Lantheus Holdings, Inc.'s debt to equity ratio high or low?

The debt to equity ratio of 0.48 is in line with its 5-year average of 0.52, near the low end of its 5-year range (0.29–1.31).

What is the TTM average debt to equity ratio for Lantheus Holdings, Inc. (LNTH)?

The TTM average debt to equity ratio for LNTH stock is 0.54.

What is the 3Y average debt to equity ratio for Lantheus Holdings, Inc. (LNTH)?

The 3Y average debt to equity ratio for LNTH stock is 0.57.

What is the 5Y average debt to equity ratio for Lantheus Holdings, Inc. (LNTH)?

The 5Y average debt to equity ratio for LNTH stock is 0.52.

What is the 10Y average debt to equity ratio for Lantheus Holdings, Inc. (LNTH)?

The 10Y average debt to equity ratio for LNTH stock is 0.76.

DATE	DEBT TO EQUITY RATIO
2026-06-30	0.48
2026-03-31	0.52
2025-12-31	0.62
2025-09-30	0.55
2025-06-30	0.53
2025-03-31	0.53
2024-12-31	0.57
2024-09-30	0.52
2024-06-30	0.60
2024-03-31	0.65
2023-12-31	0.76
2023-09-30	0.88
2023-06-30	1.07
2023-03-31	1.31
2022-12-31	1.30
2022-09-30	0.29
2022-06-30	0.33
2022-03-31	0.33
2021-12-31	0.41
2021-09-30	0.35
2021-06-30	0.35
2021-03-31	0.34
2020-12-31	0.46
2020-09-30	0.43
2020-06-30	0.44
2020-03-31	1.62
2019-12-31	1.70
2019-09-30	1.94
2019-06-30	2.16
2019-03-31	3.20
2018-12-31	3.75
2018-09-30	4.81
2018-06-30	6.00
2018-03-31	7.95
2017-12-31	11.51
2017-09-30	-3.44
2017-06-30	-3.08
2017-03-31	-2.66
2016-12-31	-2.61
2016-09-30	-2.46
2016-06-30	-2.12
2016-03-31	-2.03
2015-12-31	-1.91
2015-09-30	-1.86
2015-06-30	-1.81
2015-03-31	-1.70
2014-12-31	-1.70
2014-09-30	-1.70
2014-06-30	-1.74
2014-03-31	-1.72
2013-12-31	-1.73
2013-09-30	-1.82
2013-06-30	-1.95
2013-03-31	-2.06
2012-12-31	0.00

DATE

DEBT TO EQUITY RATIO

2026-06-30

0.48

2026-03-31

0.52

2025-12-31

0.62

2025-09-30

0.55

2025-06-30

0.53

2025-03-31

0.53

2024-12-31

0.57

2024-09-30

0.52

2024-06-30

0.60

2024-03-31

0.65

2023-12-31

0.76

2023-09-30

0.88

2023-06-30

1.07

2023-03-31

1.31

2022-12-31

1.30

2022-09-30

0.29

2022-06-30

0.33

2022-03-31

0.33

2021-12-31

0.41

2021-09-30

0.35

2021-06-30

0.35

2021-03-31

0.34

2020-12-31

0.46

2020-09-30

0.43

2020-06-30

0.44

2020-03-31

1.62

2019-12-31

1.70

2019-09-30

1.94

2019-06-30

2.16

2019-03-31

3.20

2018-12-31

3.75

2018-09-30

4.81

2018-06-30

6.00

2018-03-31

7.95

2017-12-31

11.51

2017-09-30

-3.44

2017-06-30

-3.08

2017-03-31

-2.66

2016-12-31

-2.61

2016-09-30

-2.46

2016-06-30

-2.12

2016-03-31

-2.03

2015-12-31

-1.91

2015-09-30

-1.86

2015-06-30

-1.81

2015-03-31

-1.70

2014-12-31

-1.70

2014-09-30

-1.70

2014-06-30

-1.74

2014-03-31

-1.72

2013-12-31

-1.73

2013-09-30

-1.82

2013-06-30

-1.95

2013-03-31

-2.06

2012-12-31

0.00

Debt to Equity Ratio: 0.48

LNTH Debt to Equity Ratio

LNTH Average Debt to Equity Ratio Chart

LNTH Current vs Average Debt to Equity Ratio Chart

LNTH Debt to Equity Ratio Metrics

LNTH Competitors' Debt to Equity Ratio

Financial Health

Debt to Equity Ratio Formula & Definition

Debt to Equity Ratio FAQ

LNTH Debt to Equity Ratio History

Related Metrics